Additionally, a higher prevalence of gain 19q12 in patients with high-IPR score was identified, namely, locus encoded cyclin E1 (CCNE1) and URI1, and has been previously identified to be associated with chemoresistance in ovarian cancer patients (39–41). Here, URI1 is linked to ovarian carcinoma.